Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Non Operating Income: 2019-2023

Historic Non Operating Income for ADC Therapeutics (ADCT) over the last 4 years, with Sep 2023 value amounting to -$9.3 million.

  • ADC Therapeutics' Non Operating Income rose 75.07% to -$9.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$22.3 million, marking a year-over-year decrease of 106.33%. This contributed to the annual value of -$12,080 for FY2022, which is 142.40% down from last year.
  • ADC Therapeutics' Non Operating Income amounted to -$9.3 million in Q3 2023, which was up 28.84% from -$13.0 million recorded in Q2 2023.
  • In the past 5 years, ADC Therapeutics' Non Operating Income ranged from a high of $32.1 million in Q3 2020 and a low of -$81.5 million during Q2 2020.
  • Moreover, its 3-year median value for Non Operating Income was -$1,275 (2022), whereas its average is -$1.9 million.
  • Over the last 5 years, ADC Therapeutics' Non Operating Income had its largest YoY gain of 1,813,289.83% in 2020, and its largest YoY loss of 15,320,400.75% in 2020.
  • Over the past 5 years, ADC Therapeutics' Non Operating Income (Quarterly) stood at -$1,535 in 2019, then skyrocketed by 1,813,289.83% to $32.1 million in 2020, then slumped by 129.17% to $15,929 in 2021, then slumped by 108.00% to -$1,275 in 2022, then soared by 75.07% to -$9.3 million in 2023.
  • Its Non Operating Income was -$9.3 million in Q3 2023, compared to -$13.0 million in Q2 2023 and -$3,000 in Q1 2023.